Peritoneal fluid gonadotropins and ovarian hormones in patients with ovarian cancer

被引:21
作者
Halperin, R [1 ]
Hadas, E
Langer, R
Bukovsky, I
Schneider, D
机构
[1] Tel Aviv Univ, Sackler Fac Med, Assaf Harofeh Med Ctr, Dept Obstet & Gynecol, IL-70300 Zerifin, Israel
[2] Pepto Labs, Ness Ziona, Israel
关键词
gonadotropins; ovarian cancer; ovarian hormones; peritoneal fluid; tumor marker;
D O I
10.1046/j.1525-1438.1999.99075.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The aim of this study was to examine the hormonal milieu in peritoneal fluid in ovarian cancer and control patients, and to try to identify hormonal parameters specific for ovarian cancer. The study included 41 patients: 21 with ovarian cancer and 20 patients with benign disease, constituting a control group. The peritoneal fluid and serum samples from these patients were subjected to analysis of follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol. (E-2), progesterone, testosterone, androstenedione, and dehydroepiandrosterone sulfate (DHEAS), and levels were compared between the two study groups. In addition, peritoneal fluid samples were subjected to cytologic examination and serum samples were assayed for CA 125. All the examined hormonal parameters in peritoneal fluid demonstrated a significant increase in ovarian cancer compared to control patients (P < 0.04). No significant difference in serum levels of the measured hormones was observed between the 2 groups. In order to further discriminate between patients with and without ovarian cancer, the sensitivity, specificity, positive and negative predictive values, and diagnostic accuracy of each parameter were calculated. Determination of LH in peritoneal fluid provided sensitivity, specificity and diagnostic accuracy of 100%. In conclusion patients with ovarian cancer as compared to controls demonstrate significantly increased levels of gonadotropins and ovarian hormones in peritoneal fluid, thus supporting the theory of association between ovarian cancer and specific hormonal milieu. In addition, our results provide a novel hormonal marker for discrimination between patients with and without ovarian cancer.
引用
收藏
页码:502 / 507
页数:6
相关论文
共 37 条
[1]  
[Anonymous], 1992, MANUAL STAGING CANC
[2]   PROGESTERONE AS A POSSIBLE TUMOR-MARKER FOR NON-ENDOCRINE OVARIAN MALIGNANT-TUMORS [J].
BACKSTROM, T ;
MAHLCK, CG ;
KJELLGREN, O .
GYNECOLOGIC ONCOLOGY, 1983, 16 (01) :129-138
[3]   THE POSTOPERATIVE GONADOTROPIN LEVEL IN POSTMENOPAUSAL WOMEN WITH EPITHELIAL OVARIAN-CANCER [J].
BLAAKAER, J ;
BENNETT, P ;
MICIC, S ;
TOFTAGERLARSEN, K ;
HORDING, U ;
BOCK, JE ;
LEBECH, PE .
EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 1993, 52 (02) :111-116
[4]   HORMONAL FACTORS AND PROGNOSIS IN EPITHELIAL OVARIAN-CANCER - A MULTIVARIATE-ANALYSIS [J].
BLAAKAER, J ;
HOGDALL, CK ;
HORDING, U ;
BENNETT, P ;
TOFTAGERLARSEN, K ;
DAUGAARD, S ;
BOCK, J .
EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 1993, 51 (01) :21-27
[5]  
CRAMER DW, 1992, CANCER, V74, P1318
[6]  
GARDNER WU, 1961, J NATL CANCER I, V26, P829
[7]   MALIGNANT ASCITES - CLINICAL AND EXPERIMENTAL-OBSERVATIONS [J].
GARRISON, RN ;
KAELIN, LD ;
HEUSER, LS ;
GALLOWAY, RH .
ANNALS OF SURGERY, 1986, 203 (06) :644-651
[8]   MEASUREMENT OF HUMAN CHORIONIC GONADOTROPIN-RELATED IMMUNOREACTIVITY IN SERUM, ASCITES AND TUMOR CYSTS OF PATIENTS WITH GYNECOLOGICAL MALIGNANCIES [J].
GROSSMANN, M ;
HOERMANN, R ;
GOCZE, PM ;
OTT, M ;
BERGER, P ;
MANN, K .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1995, 25 (11) :867-873
[9]  
HEINTZ APM, 1985, OBSTET GYNECOL, V66, P127
[10]   SERUM GONADOTROPINS AND STEROID-HORMONES AND THE DEVELOPMENT OF OVARIAN-CANCER [J].
HELZLSOUER, KJ ;
ALBERG, AJ ;
GORDON, GB ;
LONGCOPE, C ;
BUSH, TL ;
HOFFMAN, SC ;
COMSTOCK, GW .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 274 (24) :1926-1930